Action Adial Pharmaceuticals - ADIL

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

0,7615

Prix Achat

0,762

Prix Vente

0,796

Volume échangé

40 433

0,761 Fourchette du Jour 0,79

0,7151 Plage de 52 semaines 4,12

Cap du marché

4,878M

Clôture Veille

0,769

Ouverture

0,765

Dernière Transaction

100

0.7615

(formt)

Dernière heure de transaction

Volume financier

US$ 31 329

VWAP

0,774832

Volume moyen (3 m)

159 780

Actions en circulation

6 405 781

Rendement du Dividende

Ratio Cours sur Bénéfices

-0,99

Bénéfice par action (BPA)

-0,8

Chiffre d'affairess

Bénéfice net

-5,12M

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder.

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.adialpharma.com

Siège social

Wilmington, Delaware, USA

Fondé

Adial Pharmaceuticals Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker ADIL. Le dernier cours de clôture d'Adial Pharmaceuticals était de US$0,77. Au cours de la dernière année, les actions de Adial Pharmaceuticals ont été négociées dans une fourchette de prix de US$ 0,7151 à US$ 4,12.

Adial Pharmaceuticals compte actuellement 6 405 781 actions en circulation. La capitalisation boursière d'Adial Pharmaceuticals est de US$4,93 million. Adial Pharmaceuticals a un ratio cours/bénéfice (ratio PE) de -0.99.

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

New Patent covers claims which focus on method for identifying genetic markers in patients with alcohol or...

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

GLEN ALLEN, Va., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the...

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Completion enables the End-of-Phase 2 (EOP2) interaction with the FDA on the design of the Phase 3 program and...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.0011	0.144660704892	0.7604	0.85	0.7183	209715	0.80039044	CS
4	-0.2385	-23.85	1	1.0099	0.7151	177941	0.82757696	CS
12	-0.2385	-23.85	1	1.3	0.7151	159780	0.99443436	CS
26	-0.2091	-21.5433752318	0.9706	1.3	0.7151	151435	1.02578251	CS
52	-0.2685	-26.067961165	1.03	4.12	0.7151	2357964	1.97748483	CS
156	-51.2385	-98.5355769231	52	56.625	0.7151	1181063	5.52736167	CS
260	-39.4885	-98.1080745342	40.25	127	0.7151	1024679	23.66136578	CS

ADIL - Frequently Asked Questions (FAQ)

What is the current Adial Pharmaceuticals share price?

The current share price of Adial Pharmaceuticals is US$ 0,7615

How many Adial Pharmaceuticals shares are in issue?

Adial Pharmaceuticals has 6 405 781 shares in issue

What is the market cap of Adial Pharmaceuticals?

The market capitalisation of Adial Pharmaceuticals is USD 4,93M

What is the 1 year trading range for Adial Pharmaceuticals share price?

Adial Pharmaceuticals has traded in the range of US$ 0,7151 to US$ 4,12 during the past year

What is the PE ratio of Adial Pharmaceuticals?

The price to earnings ratio of Adial Pharmaceuticals is -0,99

What is the reporting currency for Adial Pharmaceuticals?

Adial Pharmaceuticals reports financial results in USD

What is the latest annual profit for Adial Pharmaceuticals?

The latest annual profit of Adial Pharmaceuticals is USD -5,12M

What is the registered address of Adial Pharmaceuticals?

The registered address for Adial Pharmaceuticals is CORPORATION TRUST CENTER 1209 ORANGE ST, NEW CASTLE, WILMINGTON, DELAWARE, 19801

What is the Adial Pharmaceuticals website address?

The website address for Adial Pharmaceuticals is www.adialpharma.com

Which industry sector does Adial Pharmaceuticals operate in?

Adial Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
MLGOMicroAlgo Inc	US$ 6,3767 (454,50%)	531,54M
BOXLBoxlight Corporation	US$ 3,1099 (51,70%)	1,84M
GDEVGDEV Inc	US$ 20,90 (46,56%)	264,44k
IVVDInvivyd Inc	US$ 1,7501 (44,64%)	37,75M
UPCUniverse Pharmaceuticals Inc	US$ 0,2003 (40,56%)	420,21M
DOYUDouYu International Holdings Ltd	US$ 7,19 (-55,31%)	1,28M
MNDRMobile health Network Solutions	US$ 0,5048 (-46,29%)	18,61M
BLUEbluebird bio Inc	US$ 4,09 (-41,90%)	5,44M
GCLGCL Global Holdings Ltd	US$ 3,83 (-31,48%)	635,26k
AXTIAXT Inc	US$ 1,57 (-31,44%)	6,66M
MLGOMicroAlgo Inc	US$ 6,3767 (454,50%)	531,54M
UPCUniverse Pharmaceuticals Inc	US$ 0,2003 (40,56%)	420,21M
ADTXAditxt Inc	US$ 0,0922 (-22,39%)	278,25M
NVDANVIDIA Corporation	US$ 134,43 (-4,05%)	228,15M
HOLOMicroCloud Hologram Inc	US$ 1,565 (31,51%)	190,81M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Adial Pharmaceuticals Inc (ADIL)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Adial Pharmaceuticals Inc

ADIL Dernières nouvelles

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Form 8-K - Current report

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Form S-8 - Securities to be offered to employees in employee benefit plans

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Form 8-K - Current report

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form S-1 - General form for registration of securities under the Securities Act of 1933

ADIL - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Adial Pharmaceuticals Inc (ADIL) Cours

Adial Pharmaceuticals Inc (ADIL)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Adial Pharmaceuticals Inc

ADIL Dernières nouvelles

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Form 8-K - Current report

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 8-K - Current report

Form S-8 - Securities to be offered to employees in employee benefit plans

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Form 8-K - Current report

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Form S-1 - General form for registration of securities under the Securities Act of 1933

ADIL - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités